US EditionNovartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Novartis will pay $12 billion in cash to acquire Avidity Biosciences and enhance its neuroscience pipeline with innovative RNA therapeutics for genetic neuromuscular diseases.
- On Sunday, Switzerland-based Novartis AG announced it will buy Avidity Biosciences for $12 billion, with both boards unanimously approving the deal to close in the first half of 2026.
- Avidity Biosciences Inc., developer of Antibody Oligonucleotide Conjugates, offers a platform Novartis said will advance its neuroscience strategy and complement its pipeline with potential first-in-class candidates.
- The deal's terms show Avidity Biosciences Inc. stock surged roughly 42% after the announcement, representing a 46% premium to the Friday closing share price of $49.15 and a 62% premium to the 30‑day VWAP of $44.42.
- SpinCo will be spun out to list its cardio programs with $270 million in cash, led by Kathleen Gallagher, SpinCo CEO, while Sarah Boyce, Avidity president and CEO, becomes board chair; the transaction is conditional on regulatory approvals and customary closing conditions.
- Long‑term, Novartis AG said buying Avidity will support its long‑term neuroscience strategy to launch several neuro treatments in coming years, unlocking multi‑billion‑dollar opportunities with planned product launches before 2030 and recouping billions from lost patent sales.
17 Articles
17 Articles
Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition
Avidity Biosciences brings to Novartis three RNA therapies in pivotal testing for rare neuromuscular diseases along with the technology that produced them. This platform develops drugs in a new class of targeted medicines offering potential to expand the delivery of RNA treatments beyond the liver. The post Novartis Continues RNA & Neuroscience Growth Strategy With $12B Avidity Bio Acquisition appeared first on MedCity News.
Why Avidity Biosciences Stock Blasted 42% Higher Today
Key PointsIt is being acquired for quite a meaty premium.The buyer is a top name in the global pharmaceuticals space.10 stocks we like better than Avidity Biosciences › A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below the buyout price. This leap looked quite impressive next to the S&P 500 (SNPINDEX: ^…
Novartis to Buy Avidity Biosciences for $12 Billion to Expand RNA-Based Drug Pipeline
Swiss pharmaceutical giant Novartis AG said on Oct. 26 it will acquire Avidity Biosciences Inc. for about $12 billion in cash, expanding its late-stage pipeline of RNA-based drugs for rare neuromuscular diseases. Avidity stockholders will receive $72 per share in cash, representing a 46 percent premium to the company’s closing on Oct. 24. Before the merger closes, Avidity will spin off its early-stage precision cardiology unit into a separate pu…
Novartis acquires Avidity Biosciences for US$12bn - European Biotechnology Magazine
In a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity's Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery to muscle. With the acquisition Novartis secures access to three late-stage RNA drug candidates for muscular dystrophies. Novartis agrees to acquire Avidity Biosciences for US$12bn, one of the largest RNA medicine deals, advancing three clinical…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
